Drug Profile
C 014
Alternative Names: C-014Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Curatis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inborn genetic disorders
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Inborn genetic disorders in Switzerland (unspecified route) (Curatis AG pipeline, August 2023)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Inborn genetic disorders in Switzerland
- 23 Feb 2016 Preclinical trials in Inborn genetic disorders in Switzerland (unspecified route)